Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients

Abolghasemi, Hassan. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Panahi, Yunes. Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran. Ahmadinejad, Minoo. High Institute of Research, Iranian Blood Transfusion Organization, Tehran, Iran. Toogeh, Gholamreza. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Toogeh, Gholamreza. Pharmacotherapy Department, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran. Toogeh, Gholamreza. High Institute of Research, Iranian Blood Transfusion Organization, Tehran, Iran. Toogeh, Gholamreza. Hematology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran. Toogeh, Gholamreza. Department of Pediatric Hematology-Oncology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Toogeh, Gholamreza. Golestan University of Medical Sciences, Gorgan, Iran. Toogeh, Gholamreza. Department of Thalassemia & Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran. Toogeh, Gholamreza. Doctor Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Toogeh, Gholamreza. Isfahan University of Medical Sciences, Isfahan, Iran. Toogeh, Gholamreza. Neuroscience Research Center (NRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Toogeh, Gholamreza. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Toogeh, Gholamreza. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Toogeh, Gholamreza. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Toogeh, Gholamreza. Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Karimi, Mehran. Hematology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran. Eghbali, Aziz. Department of Pediatric Hematology-Oncology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Mirbehbahani, Nargess Bigom. Golestan University of Medical Sciences, Gorgan, Iran. Dehdezi, Bighan Keikhaei. Department of Thalassemia & Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran. Badiee, Zahra. Doctor Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Hoorfar, Hamid. Isfahan University of Medical Sciences, Isfahan, Iran. Eshghi, Peyman. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Maghsoudi, Nader. Neuroscience Research Center (NRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Sahebkar, Amirhossein. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Sahebkar, Amirhossein. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Sahebkar, Amirhossein. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Gholami-Fesharaki, Mohammad. Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Journal of Pharmacopuncture.. 2018;21((2)):76-81.
Full text from:

Other resources

Abstract
Objective: This study compared the safety and efficacy of Safacto versus xyntha in patients with severe hemophilia A. Methods: Thirty-three male patients with severe hemophilia A were randomly divided into two groups. Seventeen patients received Safacto and 16 patients received Xyntha for four consecutive times. The dosage of FVIII was 40-50 IU/kg for each injection. Plasma level of FVIII activity was evaluated before every injection, 15 minutes after the injection and one month after the start of the trial. The rate of factor VIII activity, pain and joint motion were also assessed before and after the treatment. Results: Plasma level of FVIII clotting activity in Safacto and Xyntha were 1.96+/-0.5 IU/dl and 1.63+/-0.5 IU/dl and increased to 88.84+/-25.2 IU/dl and 100.09+/-17.8 IU/dl, respectively (P<0.001). Pain score and range of motion improvement were 9.3+/-0.9 and 8.7+/-0.1 in Safacto (P=0.17); and 9.4+/-0.8 and 8.8+/-0.3 in Xyntha (P=0.35), respectively. No allergic or other unfavorable reactions was observed with either of the preparations. Conclusion: This study showed that Safacto has a favorable efficacy and safety profile.
Study details
Language : English
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine